Peer-influenced content. Sources you trust. No registration required. This is HCN.

Can Novel Drug Sensitivity Patterns for Informing Personalized Therapy in Myeloid Neoplasms Be Defined?

This question is answered in Blood Advances, which features a visual abstract on how ex vivo drug screening was performed within a clinically actionable time frame (median 15 days) and predicted clinical responses in vivo.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form